The NIH Center for Regenerative Medicine

Other Stem Cells

McEwen - Pancreatic Differentiation

View PDF version

Title McEwen - Pancreatic differentiation
Date Submitted 04/2012
Submitted by Sunita D’Souza
Adapted from

Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells
M. Cristina Nostro,1 Farida Sarangi,1 Shinichiro Ogawa,1 Audrey Holtzinger,1 Barbara Corneo,2 Xueling Li,3 Suzanne J. Micallef,3 In-Hyun Park,4 Christina Basford,5 Michael B. Wheeler,5 George Q. Daley,6 Andrew G. Elefanty,3 Edouard G. Stanley,3 and Gordon Keller1*

Development. 2011 March 1; 138(5): 861–871. doi:  10.1242/dev.055236 PMCID: PMC3035090
Contributors

 

Affiliation(s) University Health Network, Toronto

Table of Contents

Introduction
Flow Chart
Materials and Reagent Preparation
Protocol
Acknowledgements
Contributors

Pancreatic – Insulin producing β cells protocol (adapted from Nostro et al., 2011)

Introduction

The generation of insulin-producing β-cells from human pluripotent stem cells is dependent on efficient endoderm induction and appropriate patterning and specification of this germ layer to a pancreatic fate. In this study, we elucidated the temporal requirements for TGFβ family members and canonical WNT signaling at these developmental stages and show that the duration of nodal/activin A signaling plays a pivotal role in establishing an appropriate definitive endoderm population for specification to the pancreatic lineage. WNT signaling was found to induce a posterior endoderm fate and at optimal concentrations enhanced the development of pancreatic lineage cells. Inhibition of the BMP signaling pathway at specific stages was essential for the generation of insulin-expressing cells and the extent of BMP inhibition required varied widely among the cell lines tested. Optimal stage-specific manipulation of these pathways resulted in a striking 250-fold increase in the levels of insulin expression and yielded populations containing up to 25% C-peptide+ cells.

Flowchart

Pancreatic differentiation flowchart

REAGENT LIST

Reagents

  Reagent Company Catalogue #

1.

anti-CXCR4-phycoerythrin (1:100)

BD

551966

2.

anti-CD31-phycoerythrin (1:100)

BD

553373

3.

anti-CD117-allophycocyanin (1: 100)

Caltag

CD11705

4.

anti-KDR–allophycocyanin (1: 10)

R&D

FAB357A

5.

HPi3 (1:20)

Novus Biologicals

NBP1-18947

6.

HPα2 (1:20)

Novus Biologicals

NBP1-18950

7.

HPx1 (1:20)

Novus Biologicals

NBP1-18951

8.

HPd1 (1:20)

Novus Biologicals

NBP1-18953

9.

anti-mouse IgG-phycoerythrin (1:100)

Jackson ImmunoResearch

715-006-150

10.

goat anti-human SOX17 (1:40)

R&D

BAF1924

11.

goat anti-FOXA2 , clone M20 (1:50)

SantaCruz

SC6554

12.

rat anti-human C-peptide (AB1921) (1:300)

BCBC consortium

AB1921

13.

mouse anti-GCG (1:500)

Sigma

G2654

14.

donkey anti-goat IgG-Alexa 488 (1:400),

Invitrogen

A11055

15.

goat anti-mouse allophycocyanin (1:200).

R&D

F0101B

16.

16% paraformaldehyde

Electron Microscopy Sciences

50980487

17.

rat anti-human C-peptide, AB1921, 1:1000

Beta Cell Biology Consortium

AB1921

18.

goat anti-human glucagon, C-18, 1:500

Santacruz

Sc-7779

19.

mouse anti-SST (AB1985; 1:500

Beta Cell Biology Consortium

AB1985

20.

goat IgG (Sigma)

Jackson ImmunoResearch

005-000-003

21.

mouse, rabbit or rat IgG

Jackson ImmunoResearch

015-000-003 / 005-000-003 / 012-000-003

22.

goat anti-mouse IgG-PE

Jackson ImmunoResearch

115-115-208

23.

donkey anti-rat IgG-Cy3

Jackson ImmunoResearch

712-166-153

24.

rabbit anti-mouse Alexa 350, 1:200

Invitrogen

A-21062

REAGENT PREPARATION

STOP MEDIUM

 

 

Final Conc.

For 40 mL

hESC WASH Medium

 

50%

20 mL

FCS

 

50%

20 mL

+/- Matrigel (1:1) *

(BD# 356 230)

1:800

100 uL

DNASE I (VWR, Cat # 80510-412, 10MU)

  1. Want final concentration to be 1mg/ml
  2. 10MU X 1X106 U X 1mg      = 153mg
        1 MU      65150 U  
  3. In the hood transfer powder to a 125 ml bottle
  4. Bring the volume up to 153 ml with ice cold sterile water
  5. Let dissolve on ice for 1-2 hours
  6. Filter and aliquot 1ml/eppendorf
  7. Store at –20.
  8. Filter sterilize, aliquot in 1 mL amounts and store frozen at -20ºC
  9. Use aliquots once and discard excess

L-ASCORBIC ACID (AA) (SIGMA # A-4544)
Prepare a stock solution of 5 mg/mL in cold TC-H2O. Leave on ice and vortex periodically until completely dissolved. Filter sterilize, aliquot and store at -20ºC. Use once and discard

MONOTHIOGLYCEROL (MTG) (SIGMA# M-6145)
The amounts of MTG indicated in our protocols are recommended concentrations. However, it is important to test each new batch of MTG as there is variability between them. MTG should be aliquoted (1 mL) and stored frozen (-20ºC). When aliquots are thawed, they can be used for several experiments and then discarded. Aliquoting of MTG is strongly recommended as it minimizes the amount of oxidation due to repeated opening

TRANSFERRIN (ROCHE# 10 652 202 )
The amounts of Transferrin indicated in our protocols are recommended concentrations. However, it is important to test each new batch of transferrin as there is variability between them. It should be aliquoted (2 mL) and stored at 4ºC.

L-Glutamine (Gibco# 25030)

TRYPSIN-EDTA (Invitrogen# 25-053-CL)

    Company Catalogue # Buffer Stock conc.

1.

Wnt3a

R&D Systems

 

PBS, 0.1%BSA, 0.5% CHAPS, 1mM EDTA

50ug/mL

2.

ActivinA

R&D Systems

338-AC/CF

PBS, 0.1%BSA

10ug/mL

3.

hBMP-4

R&D Systems

314-BP

H20, 4mM HCL, 0.1%BSA

10ug/mL

4.

hbFGF

R&D Systems

233-FB

PBS, 0.1%BSA,1mM DTT

10ug/mL

5.

hVEGF

R&D Systems

293-VE

PBS, 0.1%BSA

5ug/mL

6.

hFGF10

R&D Systems

345FG/CF

PBS, 0.1%BSA

100ug/mL

7.

hNOGGIN

R&D Systems

3344/NG

PBS, 0.1%BSA

100ug/mL

8.

Dorsomorphin

Sigma

P5499

DMSO

1mM

9.

SB431542

Sigma

S4317

DMSO

20mM

10.

L-685,458

ToCris

2627

DMSO I think now it is R&D

10mM

11.

RA

Sigma

R2625

DMSO

1mM

Serum Free Differentiation (SFD) Media

Reagent Stock conc. Working conc. Per ml 1000ml

IMDM

Cellgro

10-016-CV

75%

750ml

Ham’s F12

Cellgro

10-080-CV

25%

250ml

Penicillin/Streptomycin P/S

Invitrogen

15070-063

1%

10ml

N2 Supplement

Invitrogen

17502-048

1%

5ml

B27 Supplement

Invitrogen

12587-010

1%

10ml

7.5% BSA in PBS

10ug/ml

A9647

0.05%

6.66ml

RPMI (Gibco# 31800) supplemented with antibiotics, 10mM HEPES and 1mM Pyruvate.

(A) Day 0 Stage 1 MEDIUM

Reagent Stock conc. Working conc. Per ml

RPMI

1X

1X

1ml

Glutamine

100X

1%

10ul

MTG

26λ/2mLs

3ul/ml

3ul

Ascorbic acid

5mg/ml

50ug/ml

10ul

BMP4

10ug/ml

0.25ng/mL

0.025

bFGF

10ug/ml

5ng/mL

0.5ul

ActA

50ug/mL

100ng/mL

2ul

VEGF

5ug/mL

10ng/mL

2ul

(B) Day 1-2 Stage 1 MEDIUM

Reagent Stock conc. Working conc. Per ml

RPMI

1X

1X

1ml

Glutamine

100X

1%

10ul

MTG

26λ/2mLs

3ul/ml

3ul

ActA

5ug/mL

100ng/mL

2ul

WNT3a

50ug/mL

25ng/mL

0.5ul

(C) Day 3,5  Stage 2 MEDIUM

Reagent Stock conc. Working conc. Per ml

SFD

1X

1X

1ml

Glutamine

100X

1%

10ul

MTG

26λ/2mLs

3ul/ml

3ul

FGF10

100ug/mL

50ng/mL

0.5ul

WNT

50ug/mL

3ng/mL

0.06ul

Dorsomorphin

1mM

0.75uM

0.75ul

* Dorsomorphin is required for H1 and H9 differentiation. Other human pluripotent stem cell lines may not require Dorsomorphin at stage 2.

H21 (Gibco# 12800) with high D-glucose (4,500mg/L).

(D) Day 6,8  Stage 3 MEDIUM

Reagent Stock conc. Working conc. Per ml

H21 (high glucose)

1X

1X

1ml

Glutamine

100X

1%

10ul

B27

100X

1%

10ul

Ascorbic acid

5mg/ml

50ug/ml

10ul

Cyclopamine

0.1mM

0.25uM

2.5ul

RA

10mM

2uM

0.2ul

Noggin

100ug/ml

50ng/ml

0.5ul

FGF10

100ug/mL

50ng/mL

0.5ul

(E) Day 9,11  Stage 4 MEDIUM

Reagent Stock conc. Working conc. Per ml

H21 (high glucose)

1X

1X

1ml

Glutamine

100X

1%

10ul

B27

100X

1%

10ul

Ascorbic acid

5mg/ml

50ug/ml

10ul

SB431542

20mM

6uM

0.3ul

Noggin

100ug/ml

50ng/ml

0.5ul

(F) Day 12-20  Stage 5 MEDIUM

Reagent Stock conc. Working conc. Per ml

SFD

1X

1X

1ml

Glutamine

100X

1%

10ul

Glucose

26λ/2mLs

3ul/ml

3ul

Ascorbic acid

5mg/ml

50ug/ml

10ul

SB431542

20mM

6uM

0.3ul

Noggin

100ug/ml

50ng/ml

0.5ul

à Secretase Inhibitor
(L685,458)**

10mM

1uM

1ul

Including Glucose present in SFD, the final Glucose concentration is 40mM.
** We find that the concentration of γsecretase Inhibitor (L-685,458) can be dropped to 0.25uM.

Method

Methods
This protocol is designed for H1 and H9 human embryonic stem cell lines. Other lines may not
require Dorsomorphin at stage 2 of differentiation.

hESC maintenance
Our lab routinely adapts hESCs to trypsin passage as this allows for easy passage and the maintenance and production of large numbers of cells. Successful maintenance of healthy undifferentiated hESCs is dependent on the appropriate concentrations of feeder cells and hESCs.

Mouse Embryonic Feeder Cells (MEFs). should be approximately 80% confluent and fresh, ideally cultured for only 24 hours prior to use. If the density of the MEFs is too high (confluent) the hESCs do not form discrete colonies but rather grow as disperse groups of cells, forming a monolayer. MEFs that are too sparce (<50%) do not provide adequate support for hESC maintenance. We routinely freeze irradiated MEFs at 2x10^6 cells per vial. Each vial contains enough cells for 18-24 wells of a twelve-well plate. The plating efficiency of each batch of MEFs needs to be tested.

hESCs. hESCs should be cultured at a density that allows the growth of distinct colonies with sharp borders within 4-5 days of culture. If the cells are too dense, the developing colonies grow into each other and form a monolayer. When too few cells are cultured, they can differentiate and tend to grow slower. Our stock of hESCs are frozen at 2x10^6 cells per vial. This concentration can be used for 6-24 wells of a twelve-well plate. The number of wells that can be cultured is dependent on the hESC line as well as the extent to which they are adapted to trypsin passage. Under optimal conditions with well adapted hESCs, you should be able to reach 70% confluency 4-5 days after plating, at this stage cells are ready to be differentiated.
Note: The protocol described below is designed to be carried out in a 12-well plate format.

Day 0: Stage 1 Endoderm Progenitors

  1. Remove the medium from hESCs and wash once with RPMI.
  2. To each well, add 1mL of MEDIA (A). Incubate for 24 hours at 37°C in a 5%CO2 incubator.

Day 1-2: Stage 1 Endoderm Progenitors

  1. There will be some debris in the cultures after 24 hours. Remove MEDIA A and wash once with RPMI.
  2. To each well, add 1mL of MEDIA (B). Incubate for 24 hours at 37°C in a 5%CO2 incubator.
  3. Repeat steps 1-2 at day 2.
    Note: Endoderm induction should be evaluated by flow cytometric analysis, monitoring the cells for expression of CXCR4 (CD184) and CD117 (c-KIT). As each hESC line has its own unique kinetics, it is best to define the endoderm stage based on the CXCR4/CD117 profile rather than by time in culture. The endoderm stage is defined by the appearance of a population that co-expresses CXCR4 and CD117. Using this protocol H1 gives rise to an average of 85% CXCR4+/CD117+ cells at day 3.

Day 3: Harvest for Flow Cytometry

  1. Aspirate the medium and add 1mL of TRYPSIN-EDTA. Incubate in a 37°C incubator for 2-3 minutes and then stop the reaction with 1mL of STOP MEDIUM+DNase .
  2. Spin for 5min at 1000 RPM, aspirate and resuspend in PBS (-Ca2+-Mg2+)+10%FCS (usually 500uL per well harvested). Pass the cells through a 70 um filter to remove any clumps that are still remaining.
  3. Stain with the desired antibodies (CXCR4, CD117) according to product datasheets and perform flow cytometric analysis.

Day 3, 5 : Stage 2 Foregut/Midgut Endoderm

  1. There will be some debris in the cultures after 24 hours. Remove MEDIA B and wash once with RPMI.
  2. To each well, add 1mL of MEDIA (C).Incubate for 48 hours at 37°C in a 5%CO2 incubator.
  3. On day 5, remove MEDIA C.
  4. To each well, add 1mL of MEDIA (C). Incubate for 24 hours at 37°C in a 5%CO2 incubator.

Pancreatic differentiation image

Day 6-8: Stage 3 Pancreatic Endoderm

  1. Remove Media C.
  2. To each well, add 1mL of MEDIA (D). Incubate for 24 hours at 37°C in a 5%CO2 incubator.
  3. Repeat steps 1-2 on day 7 and 8.
    Note: Due to the high instability of RA, we tend to feed in the dark and as fast as possible during stage 3.

Day 9, 11: Stage 4 Endocrine Progenitors

  1. Remove Media D.
  2. To each well, add 1mL of MEDIA (E). Incubate for 48 hours at 37°C in a 5%CO2 incubator.
  3. On day 11, remove MEDIA E.
  4. To each well, add 1mL of MEDIA (E). Incubate for 48 hours at 37°C in a 5%CO2 incubator.

Day 13-20: Stage 5 Endocrine Cells

  1. Remove Media E.
  2. To each well, add 1mL of MEDIA (F). Incubate for 72 hours at 37°C in a 5%CO2 incubator.
  3. Feed every three days. During the course of this time hormone-expressing cells aggregate with each other and form clusters visible by eye.
  4. Harvest at day 20.
    Note: The percentage of endocrine cells should be evaluated by flow cytometric analysis, monitoring the cells for expression of C-Peptide and GCG. Below a typical profile for H1-differentiated cells at day 20.

Pancreatic differentiation image 2

Reference:

Stage-specific signaling through TGFβ family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells.
M. Cristina Nostro,1 Farida Sarangi,1 Shinichiro Ogawa,1 Audrey Holtzinger,1 Barbara Corneo,2 Xueling Li,3 Suzanne J. Micallef,3 In-Hyun Park,4 Christina Basford,5 Michael B. Wheeler,5 George Q. Daley,6 Andrew G. Elefanty,3 Edouard G. Stanley,3 and Gordon Keller1*
Development. 2011 March 1; 138(5): 861–871. doi:  10.1242/dev.055236 PMCID: PMC3035090

 

This page was last modified on October 23, 2012